TENX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
TENX is not a clear buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has strong upside potential if the upcoming Phase 3 readout is positive, but at the current price there is no proprietary buy signal, no recent news catalyst, and the technical setup is only neutral. For an impatient investor, this is not an ideal entry today. My direct view: hold and wait for confirmation rather than buy now.
Current price is 11.59, down 1.20% in regular trading and 0.55% pre-market. The MACD histogram is slightly positive at 0.0507 but is contracting, which suggests momentum is weakening rather than accelerating. RSI_6 at 37.37 is neutral-to-weak, not oversold enough to signal a strong rebound but also not extended. Moving averages are converging, which usually reflects a range-bound or undecided trend. Key levels: pivot 11.867, resistance 12.555 and 12.98, support 11.18 and 10.755. Overall, the chart looks neutral to slightly bearish in the very near term, with no strong technical breakout signal.
Cantor Fitzgerald initiated coverage with an Overweight rating and a $35 target, highlighting the setup as high-risk, high-reward and suggesting shares could double or triple if the trial succeeds. Guggenheim also raised its target to $34 from $25 and kept a Buy rating, citing encouraging clinical execution. These are strong event-driven upside catalysts.
There has been no recent news in the past week, so there is no fresh near-term momentum catalyst. The stock is still below the analyst targets but has not shown strong price action to confirm accumulation. Technical indicators are not aligned for an immediate breakout, and the short-term pattern data suggests a slightly negative next-day and next-month bias. The lack of AI Stock Picker and SwingMax signals also weakens the case for buying today.
No financial snapshot was available, so latest quarter revenue and earnings trends cannot be assessed from the provided data. The latest quarter season is not provided. Because this is a clinical-stage biotech, the investment case is driven more by trial progression than by near-term financial growth metrics.
Analyst sentiment is clearly bullish. On 2026-03-17, Cantor Fitzgerald initiated Overweight with a $35 target. On 2026-03-16, Guggenheim raised its target to $34 from $25 and kept Buy. On 2026-03-12, LifeSci Capital initiated Outperform with a $27 target. The Wall Street pros view is positive overall, with strong upside potential if the Phase 3 data is successful. The main con is that the bullish view is highly dependent on a binary clinical readout rather than steady fundamental earnings growth.
